Sensei Biotherapeutics (NASDAQ:FTH) Shares Up 8.7% – Here’s What Happened

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) shares rose 8.7% during mid-day trading on Tuesday. The stock traded as high as $20.70 and last traded at $21.1350. 126,876 shares were traded during trading, a decline of 48% from the average session volume of 244,265 shares. The stock had previously closed at $19.44.

Analysts Set New Price Targets

Several brokerages recently commented on FTH. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Monday, September 14th. JonesTrading started coverage on Sensei Biotherapeutics in a research note on Tuesday, August 4th. They set a “buy” rating and a $55.00 target price for the company. BTIG Research reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Sensei Biotherapeutics in a report on Thursday, July 16th. William Blair started coverage on shares of Sensei Biotherapeutics in a report on Friday. They set an “outperform” rating on the stock. Finally, Citizens Jmp began coverage on shares of Sensei Biotherapeutics in a research note on Monday, July 20th. They set an “outperform” rating and a $51.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Sensei Biotherapeutics currently has a consensus rating of “Buy” and a consensus price target of $56.25.

Sensei Biotherapeutics Price Performance

The company has a market capitalization of $540.26 million, a P/E ratio of -0.15 and a beta of -0.29. The business’s 50-day moving average price is $31.21.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, beating the consensus estimate of ($5.04) by $2.20. Equities analysts anticipate that Sensei Biotherapeutics, Inc. will post -13.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in FTH. Citadel Advisors LLC bought a new position in Sensei Biotherapeutics in the second quarter valued at approximately $307,000. Renaissance Technologies LLC increased its holdings in shares of Sensei Biotherapeutics by 178.2% during the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after buying an additional 20,525 shares in the last quarter. Bank of America Corp DE increased its position in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after acquiring an additional 32,719 shares during the period. Alyeska Investment Group L.P. acquired a new position in Sensei Biotherapeutics during the 2nd quarter worth about $3,610,000. Finally, Stempoint Capital LP bought a new stake in Sensei Biotherapeutics in the first quarter valued at $4,188,000. 10.50% of the stock is currently owned by institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.